Saturn V Capital Management LP
Saturn V Capital Management LP reported 24 holdings worth US$683M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Saturn V Capital Management LP reported 24 holdings worth US$683M as of Sep 30, 2026. Largest: Amylyx Pharmaceuticals, Inc., Abivax SA and Immix Biopharma, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 24
- Value as reported
- US$683M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. | 4.47M | US$130M | 19.0% |
| Abivax SA | 529K | US$52.4M | 7.7% |
| Immix Biopharma, Inc. | 4.66M | US$48.5M | 7.1% |
| Vaxcyte, Inc. | 772K | US$43.9M | 6.4% |
| Celcuity Inc. | 514K | US$40.9M | 6.0% |
| Disc Medicine, Inc. | 613K | US$40.1M | 5.9% |
| Candel Therapeutics, Inc. | 3.48M | US$36.3M | 5.3% |
| Monopar Therapeutics Inc. | 312K | US$24.9M | 3.6% |
| Vir Biotechnology, Inc. | 2.04M | US$22.8M | 3.3% |
| Trevi Therapeutics, Inc. | 1.57M | US$22.5M | 3.3% |
| X4 Pharmaceuticals, Inc. | 7.37M | US$21.4M | 3.1% |
| Alumis Inc. | 2.86M | US$21.1M | 3.1% |
| Sagimet Biosciences Inc. - Series A | 2M | US$19.8M | 2.9% |
| Dyne Therapeutics, Inc. | 837K | US$13.5M | 2.0% |
| Alto Neuroscience, Inc. | 518K | US$13.2M | 1.9% |
| Ultragenyx Pharmaceutical Inc. | 759K | US$11.4M | 1.7% |
| Zura Bio Limited | 2.03M | US$8.46M | 1.2% |
| Inhibikase Therapeutics, Inc. | 3.87M | US$7.95M | 1.2% |
| Erasca, Inc. | 514K | US$7.54M | 1.1% |
| Latigo Biotherapeutics, Inc. | 300K | US$5.02M | 0.73% |
| Satellos Bioscience Inc | 517K | US$4.39M | 0.64% |
| Invivyd, Inc. | 0 | US$0 | 0.00% |
| Ovid Therapeutics Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC